BUZZ-Brokerages await lung disease drug data from Amgen

** Brokerages await trial data presentations from Amgen

and Regeneron on Sunday as both companies vie for market share with their experimental treatments for chronic obstructive pulmonary disease (COPD)

** BMO Capital Markets believes investors will focus on how AMGN's drug Tezspire compares to REGN's Dupixent in COPD patients with high count of a type of white blood cell called eosinophil

** J.P.Morgan says Tezspire's mid-stage data looks "interesting" in the high eosinophil patient population as the drug showed 37% reduction in COPD exacerbation compared to 30% and 34% reductions seen in Dupixent late-stage trials

** However, the brokerage feels Dupixent will be well established with a "first to market advantage, a high bar set on efficacy and very broad/favorable payer coverage"

** The U.S. FDA is expected to take a decision on Dupixent's use for the treatment of COPD by June 27

** COPD is a common lung disease causing restricted airflow and breathing problems

** Up to last close, AMGN stock up 9.3% and REGN up 10.2%

(Reporting by Christy Santhosh)

((Christy.Santhosh@thomsonreuters.com))